Evidence map›Paper›PMID 38713862›Full record

ArticleDatabase : the journal of biological databases and curation2024

Pathway-based, reaction-specific annotation of disease variants for elucidation of molecular phenotypes.

Marija Orlic-Milacic, Karen Rothfels, Lisa Matthews, Adam Wright, Bijay Jassal, Veronica Shamovsky, Quang Trinh, Marc E Gillespie, Cristoffer Sevilla, Krishna Tiwari and 12 more

Abstract read
In one paragraph

Article in Database : the journal of biological databases and curation, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

22 authors.

Marija Orlic-MilacicAdaptive Oncology, Ontario Institute for Cancer Research, 661 University Avenue Suite 510, Toronto, ON M5G 0A3, Canada.ORCID 0000-0002-3218-5631
Karen RothfelsAdaptive Oncology, Ontario Institute for Cancer Research, 661 University Avenue Suite 510, Toronto, ON M5G 0A3, Canada.ORCID 0000-0002-0705-7048
Lisa MatthewsDepartment of Biochemistry and Molecular Pharmacology, New York University Grossman School of Medicine, 550 First Avenue, New York, NY 10016, USA.ORCID 0000-0001-5707-3065
Adam WrightAdaptive Oncology, Ontario Institute for Cancer Research, 661 University Avenue Suite 510, Toronto, ON M5G 0A3, Canada.ORCID 0000-0002-5719-4024
Bijay JassalAdaptive Oncology, Ontario Institute for Cancer Research, 661 University Avenue Suite 510, Toronto, ON M5G 0A3, Canada.ORCID 0000-0002-5039-5405
Veronica ShamovskyDepartment of Biochemistry and Molecular Pharmacology, New York University Grossman School of Medicine, 550 First Avenue, New York, NY 10016, USA.ORCID 0000-0002-2187-2241
Quang TrinhAdaptive Oncology, Ontario Institute for Cancer Research, 661 University Avenue Suite 510, Toronto, ON M5G 0A3, Canada.ORCID 0000-0002-3602-2290
Marc E GillespieAdaptive Oncology, Ontario Institute for Cancer Research, 661 University Avenue Suite 510, Toronto, ON M5G 0A3, Canada.ORCID 0000-0002-5766-1702
Cristoffer SevillaEuropean Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-EBI), Wellcome Genome Campus, Hinxton, Cambridgeshire CB10 1SD, UK.ORCID 0000-0002-8570-4650
Krishna TiwariEuropean Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-EBI), Wellcome Genome Campus, Hinxton, Cambridgeshire CB10 1SD, UK.ORCID 0000-0002-3699-0937
Eliot RagueneauEuropean Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-EBI), Wellcome Genome Campus, Hinxton, Cambridgeshire CB10 1SD, UK.ORCID 0000-0002-7876-6503
Chuqiao GongEuropean Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-EBI), Wellcome Genome Campus, Hinxton, Cambridgeshire CB10 1SD, UK.ORCID 0000-0001-8674-1739
Ralf StephanAdaptive Oncology, Ontario Institute for Cancer Research, 661 University Avenue Suite 510, Toronto, ON M5G 0A3, Canada.ORCID 0000-0002-4650-631X
Bruce MayAdaptive Oncology, Ontario Institute for Cancer Research, 661 University Avenue Suite 510, Toronto, ON M5G 0A3, Canada.ORCID 0000-0001-5193-0855
Robin HawAdaptive Oncology, Ontario Institute for Cancer Research, 661 University Avenue Suite 510, Toronto, ON M5G 0A3, Canada.ORCID 0000-0002-2013-7835
Joel WeiserAdaptive Oncology, Ontario Institute for Cancer Research, 661 University Avenue Suite 510, Toronto, ON M5G 0A3, Canada.
Deidre BeaversDepartment of Medical Informatics and Clinical Epidemiology, Oregon Health and Science University, 3181 S.W. Sam Jackson Park Rd., Portland, OR 97239, USA.
Patrick ConleyDepartment of Medical Informatics and Clinical Epidemiology, Oregon Health and Science University, 3181 S.W. Sam Jackson Park Rd., Portland, OR 97239, USA.
Henning HermjakobEuropean Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-EBI), Wellcome Genome Campus, Hinxton, Cambridgeshire CB10 1SD, UK.ORCID 0000-0001-8479-0262
Lincoln D SteinAdaptive Oncology, Ontario Institute for Cancer Research, 661 University Avenue Suite 510, Toronto, ON M5G 0A3, Canada.ORCID 0000-0002-1983-4588
Peter D'EustachioDepartment of Biochemistry and Molecular Pharmacology, New York University Grossman School of Medicine, 550 First Avenue, New York, NY 10016, USA.ORCID 0000-0002-5494-626X
Guanming WuDepartment of Medical Informatics and Clinical Epidemiology, Oregon Health and Science University, 3181 S.W. Sam Jackson Park Rd., Portland, OR 97239, USA.ORCID 0000-0001-8196-1177

Funding

Reactome - CoreU41HG003751 · NHGRI · ONTARIO INSTITUTE FOR CANCER RESEARCH · PI STEIN, LINCOLN D. · 2012 to 2021
$14.5M
TRAININGU54GM114833 · NIGMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LINDSEY, MERRY L., PING, PEIPEI · 2014 to 2017
$13.8M
Reactome: An Open Knowledgebase of Human Pathways.U24HG012198 · NHGRI · ONTARIO INSTITUTE FOR CANCER RESEARCH · PI Marc E Gillespie, LINCOLN D. STEIN · 2022 to 2026
$7.0M
Reactome and the Gene Ontology: Digital pathway convergence for core data resourcesU24HG011851 · NHGRI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI DEUSTACHIO, PETER G, MUNGALL, CHRISTOPHER J · 2021 to 2025
$3.6M
Centre for Therapeutic Target ValidationEuropean Bioinformatics InstituteEuropean Commission PSIMEX 223411Google Summer of Code ProgramMedicine by Design (University of Toronto)NHGRI NIH HHS 1U24HG012198 U41HG003751NHGRI NIH HHS U24 HG011851NHGRI NIH HHS U24 HG012198NHGRI NIH HHS U41 HG003751NIGMS NIH HHS U54 GM114833NIH HHS P41HG003751 U01CA239069 U54GM114833Ontario Research GL2Open Targets (The Target Validation Platform)
6 · The paper itself

Abstract

Germline and somatic mutations can give rise to proteins with altered activity, including both gain and loss-of-function. The effects of these variants can be captured in disease-specific reactions and pathways that highlight the resulting changes to normal biology. A disease reaction is defined as an aberrant reaction in which a variant protein participates. A disease pathway is defined as a pathway that contains a disease reaction. Annotation of disease variants as participants of disease reactions and disease pathways can provide a standardized overview of molecular phenotypes of pathogenic variants that is amenable to computational mining and mathematical modeling. Reactome (https://reactome.org/), an open source, manually curated, peer-reviewed database of human biological pathways, in addition to providing annotations for >11 000 unique human proteins in the context of ∼15 000 wild-type reactions within more than 2000 wild-type pathways, also provides annotations for >4000 disease variants of close to 400 genes as participants of ∼800 disease reactions in the context of ∼400 disease pathways. Functional annotation of disease variants proceeds from normal gene functions, described in wild-type reactions and pathways, through disease variants whose divergence from normal molecular behaviors has been experimentally verified, to extrapolation from molecular phenotypes of characterized variants to variants of unknown significance using criteria of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Reactome's data model enables mapping of disease variant datasets to specific disease reactions within disease pathways, providing a platform to infer pathway output impacts of numerous human disease variants and model organism orthologs, complementing computational predictions of variant pathogenicity. Database URL: https://reactome.org/.

Indexed as

Molecular Sequence AnnotationPhenotypeDatabases, GeneticDiseaseHumans

Identifiers

PMID38713862
PMCPMC11184451

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.